Here are the Form 4 insider transactions from Actuate Therapeutics, Inc. (ACTU) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACTU filings page.
Actuate Therapeutics, Inc. (ACTU) agreed to issue warrants to the Kairos Funds to purchase an aggregate 700,000 shares of common stock, subject to closing of its public offering on October 28, 2026. The warrants carry a $0.5325 exercise price, are immediately exercisable upon issuance and expire five years after the offering closes.
Actuate Therapeutics issued the Bios Entities warrants to purchase an aggregate of 3,000,000 shares of common stock at an exercise price of $0.5325 per share. The warrants were issued at the closing of the company’s public offering in consideration for a two-year lock-up of securities beneficially owned by the Bios Entities.
The three reporting persons, each identified as a director and a ten-percent owner, were Bios Fund III, LP, Bios Fund III QP, LP, and Bios Fund III NT, LP. Their reported indirect warrant acquisitions covered 126,162, 824,012, and 133,073 underlying common shares, respectively. The exercise period runs from October 28, 2026, through 5:00 p.m. New York time on October 28, 2031.
Actuate Therapeutics, Inc. (ACTU) reported warrant awards to Bios-affiliated funds and co-investment entities on October 28, 2026. The warrants are exercisable for common stock at $0.5325 per share, during a period running from October 28, 2026, through 5:00 P.M. New York time on October 28, 2031.
A footnote says the Bios Entities agreed to a two-year lock-up of issuer securities they beneficially owned, and Actuate agreed in consideration to issue warrants covering an aggregate of 3,000,000 common shares. The warrants were issued at the closing of Actuate’s public offering.
Actuate Therapeutics, Inc. (ACTU) President, CEO and Director Daniel M. Schmitt reported purchasing 140,844 common shares at $0.355 per share on October 28, 2026, in connection with the issuer’s public offering. He also acquired 70,422 detachable warrants. His direct common-stock holdings following the transaction were 442,560 shares. Separately, The Schmitt Family Irrevocable Trust held 564,071 shares; The Andrew Schmitt, The Anna Schmitt and The Edward Schmitt Irrevocable Trusts each held 22,223 shares. No Rule 10b5-1 plan is reported.
Actuate Therapeutics, Inc. reported equity compensation activity for President, CEO and Director Daniel M. Schmitt on August 14, 2026. A block of 272,056 restricted stock units vested and settled into the same number of common shares, consistent with prior grants. To cover federal and state tax withholding on this settlement, 120,521 shares of common stock were withheld by the company at a per-share value of $1.01. Following these transactions, Schmitt is also shown as trustee for several irrevocable family trusts, including one holding 564,071 common shares and others each holding 22,223 shares, which are reported as indirect ownership.
ACTUATE THERAPEUTICS, INC. director Dan Zabrowski received a grant of stock options as part of his compensation. The grant covers 15,000 options for Common Stock at an exercise price of $2.42 per share. These options were granted on May 21, 2026 and will vest in full on the one-year anniversary of the grant date. After this award, he holds 15,000 derivative securities directly, with the options scheduled to expire on May 21, 2036.
ACTUATE THERAPEUTICS, INC. director and 10% owner Todd S. Thomson received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share, vest in full on the one-year anniversary of the grant date, and expire on May 21, 2036. Certain funds managed by Kairos Venture Investments, LLC are entitled to an indirect economic interest in these options because Thomson serves on the board as their representative.
ACTUATE THERAPEUTICS, INC. director Roger Sawhney received a grant of stock options that give him the right to buy 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036.
All 15,000 options relate to common stock and were acquired as a compensation grant, not through an open-market purchase. According to the footnote, these options will vest in full on the first anniversary of the grant date, so they become exercisable after that time.
Actuate Therapeutics director Amy L. Ronneberg received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.42 per share and expire on May 21, 2036. According to the footnote, these options vest in full on the first anniversary of the grant date. Following this award, her reported derivative holdings from this grant total 15,000 options.
ACTUATE THERAPEUTICS, INC. director Jason A. Keyes received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036. According to the footnote, the options will vest in full on the first anniversary of the grant date, meaning Keyes must remain eligible through that date before the award is fully exercisable. Following this grant, his reported derivative holdings from this award total 15,000 stock options.
ACTUATE THERAPEUTICS, INC. director Martin H. Huber Jr. received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036. According to the filing, these options will vest in full on the anniversary of the grant date. Following this award, the filing shows Huber holding 15,000 stock options directly.
ACTUATE THERAPEUTICS, INC. director and ten percent owner Aaron G.L. Fletcher received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share, expire on May 21, 2036, and will vest in full on the first anniversary of the grant date. Following this grant, Fletcher holds 15,000 stock options directly.
Actuate Therapeutics reported that President and CEO Daniel M. Schmitt received a grant of employee stock options covering 237,000 shares of common stock. The options have an exercise price of $2.49 per share and expire on April 1, 2036.
All 237,000 options are shown as held directly following the transaction. According to the grant terms, 25% of the options will vest on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months.
ACTUATE THERAPEUTICS, INC. reported that Chief Operating Officer Andrew Paul Mazar received an employee stock option grant for 105,000 options to buy common stock at an exercise price of $2.49 per share.
The options expire on April 1, 2036. According to the vesting terms, 25% of the grant will vest on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months. After this grant, he holds 105,000 derivative securities directly.
ACTUATE THERAPEUTICS, INC. Chief Financial Officer Paul J. Lytle received an equity compensation grant of employee stock options for 105,000 shares of common stock. The options have an exercise price of $2.49 per share and expire on April 1, 2036.
These options will vest 25% on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months. The filing reflects a compensation-related award rather than an open-market stock purchase or sale.
Actuate Therapeutics, Inc. President and CEO Daniel M. Schmitt reported the vesting and settlement of 272,055 restricted stock units on February 13, 2026, converting into the same number of common shares at $0 per share. To cover federal and state withholding taxes, the issuer withheld 121,874 shares of common stock valued at $4.33 per share, leaving Schmitt with 150,181 directly held common shares and 272,056 RSUs outstanding. He also reports indirect ownership of additional common shares through several irrevocable family trusts for which he serves as trustee.
Actuate Therapeutics insider-related entities reported a significant share sale. On 01/05/2026, Kairos Venture Partners II, L.P., an entity associated with director and 10% owner Todd Thomson, sold 280,000 shares of Actuate Therapeutics, Inc. common stock at $5.80 per share. After this sale, Kairos Venture Partners II, L.P. indirectly held 904,795 shares. Other Kairos-managed entities reported indirect holdings of 873,033 shares by Kairos Venture Opportunities I, L.P., 321,781 shares by Kairos SPV Fund, LLC, and 254,735 shares by Kairos-Actuate SPV, L.P. The filing explains that these Kairos funds are managed and controlled by Kairos Venture Investments, LLC, and that Todd Thomson and James Demetriades may be deemed indirect beneficial owners only to the extent of their pecuniary interests.